Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155580 · ClinicalTrials.gov registry record · Phase 1
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT04155580 is a Phase 1 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT04155580, a Phase 1 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Interventions
- DRUG ASTX727
- DRUG ASTX660
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155580
The ClinicalTrials.gov registry entry for NCT04155580 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASTX727 is the first listed.
NCT04155580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04155580 about?
NCT04155580 is a clinical study titled "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)". To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
What is the current status of trial NCT04155580?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2020-06-12. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT04155580?
The interventions under investigation include: ASTX727 (DRUG), ASTX660 (DRUG).
Who is sponsoring clinical trial NCT04155580?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.